Cytori Therapeutics Inc (NASDAQ:CYTX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation. Cytori Therapeutics’ rating score has improved by 50% from three months ago as a result of various analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus target price of $1.45 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also assigned Cytori Therapeutics an industry rank of 183 out of 265 based on the ratings given to related companies.
Several research firms recently issued reports on CYTX. Maxim Group set a $2.00 target price on shares of Cytori Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 28th. Zacks Investment Research cut shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, February 13th. ValuEngine cut shares of Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, April 2nd. Laidlaw reiterated a “buy” rating and issued a $1.65 target price on shares of Cytori Therapeutics in a research note on Thursday, February 22nd. Finally, B. Riley upgraded shares of Cytori Therapeutics from a “neutral” rating to a “buy” rating in a research note on Friday, March 9th.
NASDAQ CYTX traded down $0.01 on Friday, hitting $0.28. 228,081 shares of the company’s stock traded hands, compared to its average volume of 559,256. Cytori Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.08. The stock has a market cap of $17.77, a price-to-earnings ratio of -0.43 and a beta of 3.13.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.02). Cytori Therapeutics had a negative net margin of 418.36% and a negative return on equity of 210.47%. The business had revenue of $1.50 million for the quarter, compared to analyst estimates of $2.00 million. sell-side analysts forecast that Cytori Therapeutics will post -0.18 earnings per share for the current fiscal year.
In related news, major shareholder Ag Postfinance sold 286,982 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $0.31, for a total value of $88,964.42. Following the completion of the transaction, the insider now directly owns 5,118,627 shares in the company, valued at approximately $1,586,774.37. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total transaction of $38,000.00. Following the completion of the transaction, the insider now owns 5,496,655 shares of the company’s stock, valued at $2,088,728.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 695,767 shares of company stock valued at $231,951. Company insiders own 1.90% of the company’s stock.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Vanguard Group Inc. increased its stake in Cytori Therapeutics Inc (NASDAQ:CYTX) by 81.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 612,304 shares of the biotechnology company’s stock after acquiring an additional 275,653 shares during the quarter. Vanguard Group Inc. owned approximately 1.89% of Cytori Therapeutics worth $674,000 at the end of the most recent reporting period. 6.21% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Zacks: Cytori Therapeutics Inc (CYTX) Given Average Rating of “Strong Buy” by Brokerages” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://ledgergazette.com/2018/04/15/zacks-cytori-therapeutics-inc-cytx-given-average-rating-of-strong-buy-by-brokerages.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.